FACTBOX-Drugs in development to prevent, treat influenza

LOS ANGELES, May 7 (Reuters) - Given the heightened awareness
of influenza and the threat of a global pandemic, it is not
surprising that the pharmaceutical industry is dedicating
significant research efforts to the development of new
therapeutics.

The following table presents a comprehensive overview of
influenza drugs and other antiviral agents that have made it to
testing in humans. Scores of other therapies are in earlier stages
of development, including animal testing.
Drug Name Organization Status
CSL-401 CSL Ltd (CSL.AX) Registered
Fluad-H5N1 Novartis AG (NOVN.VX) Registered
GSK-1119711A GlaxoSmithKline PLC (GSK.L) Registered
Grippol Plus Solvay SA (SOLB.BR) Registered
Influvac TC Solvay Registered
Intradermal seasonal
flu vaccine Sanofi-Aventis SA (SASY.PA) Registered
Pandemrix GlaxoSmithKline Registered
Panflu Sinovac (SVA.A) Registered
Celvapan Baxter (BAX.N) Recommended

approval
634858 GlaxoSmithKline Recommended

approval
FluBlok Emergent BioSolutions EBS.N>Pre-Registered
H5N1 pandemic
influenza vaccine Biken/ Kitasato Institute/

Denka Pre-Registered
H9N2 avian
influenza vaccine Novartis Pre-Registered
Flu infants Sanofi-Aventis Phase III
Fluval H5N1 Omninvest Phase III
GC-501 Green Cross Phase III
GSK-1557484A GlaxoSmithKline Phase III
GSK-2186877A GlaxoSmithKline Phase III
GSK-576389A GlaxoSmithKline Phase III
Grippol TC Solvay Phase III
Peramivir Shionogi (4507.T) Phase III
Pre-pandemic
MF59-adjuvanted
H5N1 vaccine Novartis Phase III
R-118958 Daiichi Sankyo (4568.T) Phase III
VCIV Baxter Phase III
Atvogen HemispheRx (HEB.A) Phase II
CSL-412 CSL Phase II
Favipiravir Toyama Phase II
FluCell Sanofi/Crucell (CRCL.AS) Phase II
GSK-1247446A GlaxoSmithKline Phase II
LAIV BioDiem Phase II
463263 Intercell Phase II
434372 Novavax Phase II
427232 Crucell Phase II
394549 Sanofi Phase II
460762 Sinovac Phase II
426173 Solvay/ Norwood Phase II
430974 Novavax Phase II
AVX-502 AlphaVax Phase I/II
Human leukocyte
interferon alpha HemispheRx Phase I/II
UMN-0501 UMN Pharma Phase I/II
423250 Baylor College of Medicine Phase I/II
424477 Vaxine Phase I/II
473074 Nat. Inst. Allergy &

Infectious Dis. Phase I/II
ADnVN1203/04.H5 Vaxin Phase I
Agrippal-IC31 Novartis/Intercell Phase I
DAS-181 NexBio Phase I
Flagellin.HuHa/
flagellin.AvHA VaxInnate Phase I
Flagellin.HuM2e VaxInnate Phase I
Fluvacc Avir Green Hills Biotechnology Phase I
Fluzone/JVRS-100 Juvaris Phase I
GBH-04L1 Avir Green Hills Biotechnology Phase I
GHB-01L1 Avir Green Hills Biotechnology Phase I
GSK-2115160A GlaxoSmithKline Phase I
H6N1-Teal-HK
97/AA Nat. Inst. Allergy &

Infectious Dis. Phase I
M2e-HBc Sanofi-Aventis/ Acambis Phase I
MEDI-566 AstraZeneca Phase I
PER.C-flu Sanofi/ Crucell Phase I
PIA-0601 PowderMed Phase I
QS-21 Acambis ACM.SG Phase I
SCH-900795 BioDiem/Nobilon Phase I
V-512 Merck & Co (MRK.N) Phase I
VCL-IPM1 Vical (VICL.O) Phase I
VCL-IPT1 Vical Phase I
VRCAVIDNA036-00-VP Nat. Inst. Allergy &

Infectious Dis. Phase I
VRCFLUDNA047-00-VP Nat. Inst. Allergy &

Infectious Dis. Phase I
Vaxfectin Vical Phase I
428363 MedImmune/National

Institutes of Health Phase I
468374 US Department of Health

& Human Services Phase I
655089 University of Bergen Phase I
458108 Novavax/Nat. Inst. Allergy

& Infectious Dis. Phase I
646010 Sanofi Phase I
649281 Baxter Phase I
477348 Nat. Inst. Allergy &

Infectious Dis./ Baylor

College of Medicine Phase I
457691 Nat. Inst. Allergy &

Infectious Dis. Phase I
446676 GlaxoSmithKline Phase I
427488 Generex (GNBT.O) Phase I

Source: Thomson Reuters Life Sciences group